Bayer and Johnson & Johnson are facing at least 220 Xarelto bleeding lawsuits, which have been consolidated as part of a centralized multi-district litigation (MDL) in a Louisiana federal court. These cases, many of which were combined in December 2014, allege that the drugmakers failed to warn patients about the serious and potentially fatal side effects of its anti-coagulant Xarelto (for which there is no bleeding antidote), and unlawfully marketed the drugs to patients. In February 2015, the Court advanced the progress of the litigation by appointing a leadership structure, which includes G&E’s Director Elizabeth Graham as chair of one of the MDL’s principal guidance committees. The committee will advocate on behalf of plaintiffs injured or killed by side effects of the drug. In addition to the consolidated Louisiana litigation, a number of other similar suits are proceeding in state courts across the country.